BIOL vs. BBLG, OPGN, ALLR, RSLS, AKAN, SQZ, INFI, MOTS, NBY, and SCPS
Should you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Bone Biologics (BBLG), OpGen (OPGN), Allarity Therapeutics (ALLR), ReShape Lifesciences (RSLS), Akanda (AKAN), SQZ Biotechnologies (SQZ), Infinity Pharmaceuticals (INFI), Motus GI (MOTS), NovaBay Pharmaceuticals (NBY), and Scopus BioPharma (SCPS). These companies are all part of the "medical" sector.
BIOLASE vs.
Bone Biologics (NASDAQ:BBLG) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.
Bone Biologics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -57.00%. BIOLASE's return on equity of -123.42% beat Bone Biologics' return on equity.
In the previous week, BIOLASE had 3 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for BIOLASE and 0 mentions for Bone Biologics. BIOLASE's average media sentiment score of 0.00 beat Bone Biologics' score of -0.01 indicating that Bone Biologics is being referred to more favorably in the media.
Bone Biologics has higher earnings, but lower revenue than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
BIOLASE has a consensus price target of $513.50, indicating a potential upside of 32,205.76%. Given Bone Biologics' higher probable upside, analysts plainly believe BIOLASE is more favorable than Bone Biologics.
BIOLASE received 286 more outperform votes than Bone Biologics when rated by MarketBeat users.
Summary
BIOLASE beats Bone Biologics on 8 of the 13 factors compared between the two stocks.
Get BIOLASE News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools